Download Files:
(Z)-Orantinib
$38 – $270
Products Details
Product Description
– (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. (Z)-Orantinib is a potent antiangiogenic and antitumor agent that induces regression of established tumors[1][2].
Web ID
– HY-10517A
Storage Temperature
– -20°C, 3 years; 4°C, 2 years (Powder)
Shipping
– Room Temperature
Applications
– Cancer-Kinase/protease
Molecular Formula
– C18H18N2O3
References
– [1]Laird AD, et, al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res. 2000 Aug 1;60(15):4152-60.|[2]Laird ad, et, al. SU6668 inhibits Flk-1/KDR and PDGFRbeta in vivo, resulting in rapid apoptosis of tumor vasculature and tumor regression in mice. FASEB J. 2002 May;16(7):681-90.
CAS Number
– 210644-62-5
Molecular Weight
– 310.35
Compound Purity
– 99.02
SMILES
– O=C(O)CCC1=C(C)NC(/C=C2C(NC3=C2C=CC=C3)=O)=C1C
Clinical Information
– No Development Reported
Research Area
– Cancer
Solubility
– DMSO : 50 mg/mL (ultrasonic)
Target
– FGFR;PDGFR;VEGFR
Isoform
– FGFR1;PDGFRβ;VEGFR2/KDR/Flk-1
Pathway
– Protein Tyrosine Kinase/RTK
Product type
– Reference compound
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
